The American journal of medicine
The American journal of medicine
Audio Summaries
Every issue of The American journal of medicine moves the field forward, but reading every paper cover-to-cover isn't realistic. OSLR turns each article into a 3-minute audio summary so you can stay current while you commute, round, or work out.
Recent summaries
The latest articles summarized from The American journal of medicine.
Impact of weight reduction therapies on fibrosis and adverse liver outcomes in metabolic dysfunction-associated liver disease: an evidence-based review.
Nov 20, 2026
This evidence-based review asks whether weight reduction therapies (lifestyle, bariatric/metabolic surgery, and pharmacotherapies) improve liver fibrosis, noninvasive stiffness measures, and major adverse liver outcomes (MALO) in metabolic dysfunction-associated steatohepatitis (MASH). The authors find that multimodal weight loss is generally associated with fibrosis regression and lower MALO risk, but heterogeneity across studies and limited evidence that weight loss independently drives these benefits temper the conclusions. They recommend continued monitoring of patients with MASH and fibrosis, with MASH-specific pharmacotherapy considered for non-cirrhotic patients with moderate-to-advanced fibrosis (F2-F3), alongside diet and exercise.
The Comparative Safety of Tramadol versus Oxycodone after Major Procedures, in Patients with Cirrhosis.
Nov 19, 2026
This retrospective cohort study used two U.S. claims databases to compare liver decompensation risk in patients with cirrhosis who started tramadol or oxycodone within 30 days after a major surgical procedure, using propensity score matching. The authors asked whether tramadol, which some guidelines advise against in cirrhosis, is less safe than oxycodone for this population. They found no significant difference in 90-day liver decompensation (HR 1.06, 95% CI 0.93-1.21) or in any secondary outcomes, suggesting tramadol may be a comparably safe option, though formulation and dosing questions remain open.
Trends in cirrhosis-related mortality stratified by sex and race/ethnicity in the United States, 2018-2024.
Nov 19, 2026
This population-based study examined how US cirrhosis-related mortality changed from 2018 to 2024 among adults aged 25 and older, stratified by sex and race/ethnicity. The authors asked whether cirrhosis deaths shifted during the COVID-19 pandemic and how burden differed across groups. They found mortality peaked in Q4 2020, was highest among non-Hispanic American Indian or Alaska Native individuals, was consistently higher in males, and females showed a steeper overall increase with a slower later decline.
Behind the Breathlessness: Defining Pulmonary Phenotypes in Post-COVID Syndrome.
Nov 18, 2026
This retrospective single-center study asked whether persistent breathlessness after COVID-19 with normal routine lung function hides distinct pulmonary disorders. Of 122 patients, most were classified as alveolitis/ILD-dominant (50%) or bronchiolitis-dominant (38.5%), with asthma-dominant presentations in 9%, and the authors observed small improvements in FEV₁, FVC, DLCO, and RV/TLC after phenotype-directed management. Because the study was uncontrolled, these modest changes cannot establish treatment efficacy or quality-of-life benefit, and prospective controlled trials are needed.
Creatinine-Only eGFR in the Low-eGFR-Only Phenotype of Diabetic Kidney Disease.
Nov 18, 2026
This letter examines whether the choice of filtration marker affects how participants are classified into diabetic kidney disease phenotypes, using a UK Biobank analysis that found higher cardiovascular death risk in low eGFR without albuminuria than in albuminuria alone. The authors ask whether the creatinine-only eGFR used in the original study, rather than the creatinine-cystatin C equation KDIGO recommends when cystatin C is available, could change phenotype assignment. They report that cystatin C-based eGFR below 60 is more common than creatinine-based eGFR below 60 (13.7% versus 9.7% in a meta-analysis), so phenotype membership depends on the marker, and they propose a creatinine-cystatin C re-analysis to determine how many of the 758 low-eGFR-only participants would be reclassified and whether the hazard ratio of 2.42 holds.
Injurious Falls and Mortality With Intensive Blood Pressure Treatment in SPRINT.
Nov 16, 2026
Using data from 9,361 SPRINT participants, this secondary analysis asked whether injurious falls, or their timing relative to a fall, modify the association between intensive systolic blood pressure treatment (<120 mm Hg) and all-cause mortality compared with standard treatment (<140 mm Hg). Intensive treatment was associated with lower mortality both in participants with and without injurious falls, and in analyses before and after a fall, with no significant interaction (all Pint >0.8). The authors conclude that falls did not alter the mortality benefit of intensive treatment, though estimates after a fall were imprecise due to small numbers.
Enterococci as Emerging Pathogens in Infective Endocarditis and Cardiac Device Infections: Future Implications.
Nov 7, 2026
This review examines the growing role of enterococci as cardiac pathogens, particularly in infective endocarditis after TAVR and in cardiac implantable electronic device (CIED) infections, driven by an aging population and expanding use of prosthetic valves and devices. The authors highlight that Enterococcus faecalis remains the main cardiac species of concern due to its strong adhesion to damaged tissue and prosthetic surfaces, biofilm tolerance, and frequent occult endocarditis during bacteremia, while Enterococcus faecium poses a future threat because of its hospital-adapted, multidrug-resistant lineages. They conclude that rising device-related risk may increase the absolute disease burden, calling for linked, species-level surveillance integrating bacteremia, imaging, recurrence, resistance, and genomic data.
Cervical Spinal Stenosis as an Extracardiac Sentinel for Non-AL Amyloidosis in Older Adults.
Nov 2, 2026
Using propensity-matched TriNetX data on adults aged 60 and older, this study asked whether cervical spinal stenosis is linked to later coded non-light-chain amyloidosis. Cervical stenosis was associated with a modest increase in risk compared with lumbar stenosis (HR 1.138) and a roughly two-fold increase compared with hip or knee osteoarthritis (HR 1.958). Exploratory analyses suggested that older age, female sex, and preserved kidney function identify a higher-yield subgroup, though the findings do not establish a validated risk score or absolute-risk hierarchy.
Hepatocellular Jaundice as an Atypical Hepatic Manifestation of Disseminated Gonococcal Infection: A Case Report.
Nov 2, 2026
This case report describes a 46-year-old man with poorly controlled diabetes who developed disseminated gonococcal infection (arthritis-dermatitis syndrome) complicated by conjugated hyperbilirubinemia and hepatocellular injury, without perihepatitis or genitourinary symptoms. The authors asked whether direct hepatocellular liver injury can occur in disseminated gonorrhea independent of Fitz-Hugh-Curtis syndrome and in patients without a reported high-risk sexual history. Blood cultures confirmed N. gonorrhoeae, and the liver injury fully resolved with ceftriaxone and doxycycline, supporting the view that clinicians should maintain suspicion and order blood cultures and site-specific NAATs even when exposure history is unremarkable.
Current development of therapeutic strategies for Alzheimer's disease.
Oct 31, 2026
This review surveys current therapeutic strategies for Alzheimer's disease, organized around a three-phase model: amyloid-β deposition, intraneuronal p-tau tangles, and downstream effector pathways causing neuronal damage. The author reports that anti-Aβ antibodies slowed cognitive decline by about 26% but caused brain swelling or hemorrhage in roughly 30% of patients, while anti-p-tau antibodies reduced tau burden without cognitive benefit. Early human and mouse studies of phase III targets (e.g., intersectin-1 inhibition, PD-1 blockade, and oxidative stress reduction) are also highlighted as promising directions.
